Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Project Oncology®
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS; Daniel Landi, MD
- Alexandria May, PharmD, BCPS
- Daniel Landi, MD
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
0.75 program credits
- Saad Z. Usmani, MD, MBA
0.75 program credits
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Project Oncology®
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Project Oncology®
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD; John Mascarenhas, MD
- Shelina Ramnarine, PhD
- John Mascarenhas, MD
- Marina Kremyanskaya, MD
Gastric Cancer Prevention: A Risk-Based Approach
Gastric Cancer Prevention: A Risk-Based Approach
GI Insights
Gastric Cancer Prevention: A Risk-Based Approach
Peter Buch, MD, FACG, AGAF, FACP; Chul Hyun, MD, PhD, MPH
- Peter Buch, MD, FACG, AGAF, FACP
- Chul Hyun, MD, PhD, MPH
Improving Long-Term Adherence to CRC Screening Recommendations
Improving Long-Term Adherence to CRC Screening Recommendations
Clinician's Roundtable
Improving Long-Term Adherence to CRC Screening Recommendations
Brian P. McDonough, MD, FAAFP; David A. Lieberman, MD
- Brian P. McDonough, MD, FAAFP
- David A. Lieberman, MD

Medical News

Medical News
ROI Dilation Disrupts Pediatric Brain Tumor ADC Radiomics
08/24/2026
Read more
Medical News
Mental Health Comorbidity Raises Acute Care Use in Cancer
08/17/2026
Read more
Medical News
BACE Added to Tislelizumab Improved Response in Bulky NSCLC
08/17/2026
Read more
Medical News
CT Body Composition Misses Cancer Nutritional Risk
08/17/2026
Read more

CME/CE

Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits
MinuteCE®
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 credits 4 episodes
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 credits 4 episodes
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
MinuteCE®
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
MinuteCE®
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 credit 5 episodes
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 credit 5 episodes

Clinical Practice

Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Project Oncology®
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
Supporting Patients Throughout Urothelial Carcinoma Treatment
Supporting Patients Throughout Urothelial Carcinoma Treatment
Project Oncology®
Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Project Oncology®
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP; Douglas A. Tremblay, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Douglas A. Tremblay, MD
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit

Programs

Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
CME/CE
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS; Ghayas Issa, MD
0.50 credits
- Amer Zeidan, MBBS
- Ghayas Issa, MD
0.50 credits
CME/CE Virtual Event
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
0.50 credits
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Axatilimab’s Impact on cGVHD and Associated BOS
Axatilimab’s Impact on cGVHD and Associated BOS
Project Oncology®
Axatilimab’s Impact on cGVHD and Associated BOS
Charles Turck, PharmD, BCPS, BCCCP; Amandeep Salhotra, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Amandeep Salhotra, MD